可注射可回收水杨酸钙水凝胶在比格犬根尖周炎模型中促进持续性根尖周骨再生
本研究在2只比格犬的18颗单根牙上诱导根尖周病变,随机分为F127-DMA/CASA水凝胶、氢氧化钙和空白对照三组,通过CBCT三维体积分析追踪10周。F127-DMA/CASA组总体平均病变体积缩小54%,显著优于对照组26%和氢氧化钙组38%(P < .03),并在两颗治疗牙中观察到新骨形成。体外实验显示人成骨细胞暴露于该水凝胶后,所有目标成骨标志物mRNA水平增加3至25倍,并出现类骨矿物质沉积。
要点
- F127-DMA/CASA水凝胶组10周病变体积缩小54%,优于氢氧化钙38%和对照26%。
- 该水凝胶在2至6周持续加速愈合,速率显著高于氢氧化钙和对照。
- 两颗CASA治疗牙出现新骨形成,体外成骨标志物mRNA增加3至25倍。
核心结论
- F127-DMA/CASA水凝胶在临床相关动物模型中实现优于传统药物的持续根尖周愈合和骨再生。
研究设计与样本
- 在2只比格犬的18颗单根牙上诱导根尖周病变,随机分为F127-DMA/CASA、氢氧化钙和未治疗对照三组。
- CASA和氢氧化钙组根管内放置药物4周后去除,对照组不放药。
- 通过CBCT和三维体积分析追踪用药后10周内的根尖周病变体积。
- 体外将人成骨细胞暴露于水凝胶,用RT-qPCR评估成骨标志物表达,用光谱分析和电镜表征矿物质沉积。
主要发现
- F127-DMA/CASA组总体平均病变体积缩小54%,显著优于对照组26%和氢氧化钙组38%(P < .03)。
- 愈合呈3种不同速率:0至2周最快,CASA与氢氧化钙相似且仅中等快于对照。
- 氢氧化钙和对照组2周后进入平台期,第10周仅分别再增加10%和6%。
- CASA组2至6周仍保持显著更高速率20%,6至10周减慢至6%,但仍高于氢氧化钙和对照。
- 两颗CASA治疗牙观察到新骨形成;体外成骨细胞暴露于CASA后所有目标成骨标志物mRNA水平增加3至25倍,并出现 robust 类骨矿物质沉积。
临床怎么用
- 该水凝胶可作为根管内药物,兼具抗菌与成骨诱导潜力,可能超越传统消毒功能。
- 需在临床相关动物模型中进一步验证后,再考虑临床转化。
局限性
- 样本量小(2只比格犬、18颗牙),结论需更大规模研究验证。
- 观察期仅10周,长期疗效和安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Persistent apical periodontitis remains a clinical challenge requiring both effective disinfection and bone regeneration. This study tested the hypothesis that an injectable, retrievable F127-dimethacrylamide (DMA)/calcium salicylate (CASA) hydrogel facilitates periapical bone healing by combining antimicrobial action with osteogenic induction. METHODS: Periapical lesions were induced in 18 single-rooted teeth of 2 beagle dogs. After the periapical lesions were confirmed, teeth were randomly assigned to 3 groups: F127-DMA/CASA, calcium hydroxide (Ca(OH)2), or an untreated control. For the CASA and Ca(OH)2 groups, intracanal medicaments were placed and then removed after 4 weeks; in the control group, the root canals were left without the medicament. Periapical lesion volumes were tracked via cone-beam computed tomography and three-dimensional volumetric analysis for up to 10 weeks postmedication. In vitro, human osteoblasts were exposed to the hydrogel to evaluate osteogenic marker expression by reverse-transcription -quantitative polymerase chain reaction and to characterize mineral deposition by spectroscopic analysis and electron microscopy. RESULTS: The F127-DMA/CASA group achieved the highest overall mean lesion volume reduction (54%) and significantly outperformed both control (26%) and Ca(OH)2 treatment (38%) at 10-weeks (P < .03). Healing progressed at 3 different rates. The fastest occurred at 0-2 weeks, corresponding to initial cleaning of the canal, where Ca(OH)2 and CASA were similar to each other and only moderately faster than control. Ca(OH)2 and control reached a plateau after 2 weeks, with only a small subsequent increase (10% and 6%, respectively) at week 10. In contrast, CASA continued to show a significantly higher rate (20%) between weeks 2 and 6, which slowed (6%) between weeks 6 and 10, but remained higher than Ca(OH)2 and control. A surprising result was the observation of new bone formation in two of the CASA-treated teeth. These results were further supported by auxiliary in vitro experiments in which osteoblasts exposed to CASA showed a 3- to 25-fold increase in mRNA levels of all targeted osteogenic markers and robust bone-like mineral deposition. CONCLUSIONS: The F127-DMA/CASA hydrogel achieved superior, sustained periapical healing and demonstrated bone regeneration as compared with conventional medicaments in a clinically relevant animal model. These outcomes were supported in vitro, exposing the molecular upregulation of osteoblast maturation markers and deposition of bone analog minerals, suggesting that the system functions as a bioactive regenerative therapy beyond traditional disinfection.
引用
- Aguilar Perez FJ, Mahmoud AH, Cui M, et al. Injectable and Retrievable Calcium Salicylate Hydrogel Promotes Sustained Periapical Bone Regeneration in a Beagle Dog Model of Apical Periodontitis. J Endod. 2026. PMID: 42810677. doi:10.1016/j.joen.2026.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。